Home

The Korea Herald

Latest news

Most Popular

  1. 1

    1 in 3 Koreans live alone, family types becoming diverse

    1 in 3 Koreans live alone, family types becoming diverse
  2. 2

    Korea, Japan finance chiefs vow to tame rampant FX market volatility

    Korea, Japan finance chiefs vow to tame rampant FX market volatility
  3. 3

    US 'incredibly concerned' about suspected NK-Iran military ties

    US 'incredibly concerned' about suspected NK-Iran military ties
  4. 4

    K-pop group's manager dismissed for setting up spycam in theater dressing room

    K-pop group's manager dismissed for setting up spycam in theater dressing room
  5. 5

    K-pop singer lost consciousness after being hit by foul ball, cancels show

    K-pop singer lost consciousness after being hit by foul ball, cancels show
  1. 6

    Korean Muslim YouTuber's plan to build mosque in Incheon goes viral

    Korean Muslim YouTuber's plan to build mosque in Incheon goes viral
  2. 7

    [Kim Seong-kon] Democracy and the future of South Korea

    [Kim Seong-kon] Democracy and the future of South Korea
  3. 8

    Why is Apple Pay struggling to get purchase in Korea?

    Why is Apple Pay struggling to get purchase in Korea?
  4. 9

    Yoon's office denies considering liberal figures for key posts

    Yoon's office denies considering liberal figures for key posts
  5. 10

    Seoul says Fu Bao loan 'not going to happen'

    Seoul says Fu Bao loan 'not going to happen'
지나쌤

Samsung BioLogics files administrative lawsuit against FSC ruling

By Yonhap

Published : Nov. 28, 2018 - 09:05

    • Link copied

Samsung BioLogics said Wednesday it has filed an administrative lawsuit against a recent ruling by the country‘s financial regulator that the company violated accounting rules.

Samsung BioLogics, the biotechnology unit of Samsung Group, also asked the Seoul Administrative Court to nullify penalties that were imposed by the Financial Services Commission (FSC) over the ruling. 

(Yonhap) (Yonhap)

After months of regulatory review, the Securities and Futures Commission under the FSC ruled earlier this month that Samsung BioLogics intentionally inflated the value of its affiliate, Samsung Bioepis Co., ahead of its listing in 2016.

The FSC also decided to impose a fine of 8 billion won (US$7.1 million) against Samsung BioLogics and recommended the firm dismiss its chief executive due to responsibility for the accounting breach.

The regulatory review centered on questions about Samsung BioLogics’ sudden profits in 2015 after years of losses. Samsung BioLogics reported a net profit of 1.9 trillion won that year after changing the method used to calculate the value of Samsung Bioepis, which is a joint venture with the U.S.-based Biogen Inc.

Samsung BioLogics has claimed that the change in accounting methods was in line with international accounting standards.

Trading of Samsung BioLogics shares has been suspended since the ruling was announced and the listing of its shares on the local bourse is under review. (Yonhap)

More from Headlines